Clinical Policy: Hemin (Panhematin)
Reference Number: CP.PHAR.181
Effective Date: 02.01.16
Last Review Date: 02.19
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Hemin for injection (Panhematin®) is an enzyme inhibitor derived from processed red blood cells.

FDA Approved Indication(s)
Panhematin is indicated for amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitation(s) of use:
• Before administering Panhematin, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).
• Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. Panhematin therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. Panhematin is not effective in repairing neuronal damage.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Panhematin is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Acute Porphyria (must meet all):
      1. Diagnosis of acute porphyria (i.e., acute intermittent porphyria [AIP], variegate porphyria [VP], or hereditary coproporphyria [HCP]) confirmed by presence of clinical symptoms (e.g., abdominal pain, pain in chest, legs or back, peripheral neuropathy, hypernatremia, tachycardia, sweating, tremor, dysuria, incontinence, constipation, nausea, vomiting) and one of the following (a or b):
         a. For AIP: urine positive for prophobilinogen (PBG);
         b. For VP or HCP: urine positive for PBG; or elevated urinary porphyrins with elevated plasma and/or fecal porphyrins;
      2. Age ≥ 16 years;
      3. Dose does not exceed 6 mg/kg in any 24-hour period.
      Approval duration: 14 days
B. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. Acute Porphyria (must meet all):
      1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, new dose does not exceed 6 mg/kg in any 24-hour period.
      Approval duration: Up to 14 days
   
   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
         Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   AIP: acute intermittent porphyria  
   PBG: prophobilinogen  
   FDA: Food and Drug Administration  
   VP: variegate porphyria  
   HCP: hereditary coproporphyria

   Appendix B: Therapeutic Alternatives
   Not applicable

   Appendix C: Contraindications/Boxed Warnings
   • Contraindication(s): Do not use in patients with known hypersensitivity to Panhematin  
   • Boxed warning(s): none reported

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amelioration of recurrent attacks of</td>
<td>1 to 4 mg/kg/day IV for 3 to 14 days based on the clinical signs. The standard dose in clinical practice is 3 to 4 mg/kg/day.</td>
<td>6 mg/kg in any 24-hour period.</td>
</tr>
</tbody>
</table>
Indication | Dosing Regimen | Maximum Dose
--- | --- | ---
acute intermittent porphyria | Repeat dose in more severe cases no earlier than every 12 hours. Do not exceed 6 mg/kg in any 24-hour period. | |

VI. Product Availability
Single-dose lyophilized powder vial: 350 mg

VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1640</td>
<td>Injection, hemin, 1 mg</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Details</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed</td>
<td>02.16</td>
<td>03.16</td>
</tr>
<tr>
<td>Removed requirement that medication is prescribed by a physician experienced in porphyria. Removed warnings against hypersensitivity reactions. Removed exclusion to treatment because of the presence of porphyria cutanea tarda. Added examples of some clinical symptoms. Changed approval duration from 3 months to 14 days per PI.</td>
<td>03.17</td>
<td>03.17</td>
</tr>
<tr>
<td>1Q18 annual review: no significant changes; references reviewed and updated.</td>
<td>11.20.17</td>
<td>02.18</td>
</tr>
<tr>
<td>1Q 2019 annual review: added commercial line of business to policy; continued approval duration updated to “up to” 14 days; no significant changes; references reviewed and updated.</td>
<td>10.30.18</td>
<td>02.19</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional...
organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.